Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Option B+ in Nigeria: New study supports lifelong antiretroviral treatment for pregnant women with HIV
The following is a guest post by Biyi Adesina of Avenir Health, Chukwuma Anyaike of the Ministry of Health, Nigeria, and Sara Bowsky of the Futures Group According to a 2013 […]
A program that screened more than 7000 inmates for tuberculosis at four South Africa correctional facilities showed that a large number of inmates could be diagnosed […]
The results of a new study support something advocates both domestically and globally have been pushing for years: organ donation from people infected with HIV to […]
Analysis shows donors pledged more than asked, but delivery lags, while responders say gaps in outbreak control can reverse progress When the World Health Organization issued […]